Exelixis
EXEL
#1725
Rank
C$13.65 B
Marketcap
$47.83
Share price
-1.16%
Change (1 day)
53.35%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total debt

Total debt on the balance sheet as of September 2024 : C$0.27 Billion

According to Exelixis's latest financial reports the company's total debt is C$0.27 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Exelixis - Total debt on balance sheet (from 2000 to 2024)

Total debt by year

Year Total debt Change
2023-12-31C$0.25 B-2.37%
2022-12-31C$0.25 B294.92%
2021-12-31C$65.34 M4.4%
2020-12-31C$62.58 M-0.19%
2019-12-31C$62.7 M208.61%
2018-12-31C$20.31 M8.19%
2017-12-31C$18.78 M-92.61%
2016-12-31C$0.25 B-56.16%
2015-12-31C$0.57 B39.95%
2014-12-31C$0.41 B12.07%
2013-12-31C$0.36 B10.72%
2012-12-31C$0.33 B80.82%
2011-12-31C$0.18 B-11.39%
2010-12-31C$0.20 B148.74%
2009-12-31C$83.77 M-41.45%
2008-12-31C$0.14 B18.04%
2007-12-31C$0.12 B-14.42%
2006-12-31C$0.14 B-18.27%
2005-12-31C$0.17 B-2.09%
2004-12-31C$0.17 B22.82%
2003-12-31C$0.14 B23.4%
2002-12-31C$0.11 B49.77%
2001-12-31C$77.96 M248.1%
2000-12-31C$22.39 M16.76%
1999-12-31C$19.18 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
C$30.87 B 10,953.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
C$36.58 B 12,994.04%๐Ÿ‡ซ๐Ÿ‡ท France
C$54.78 B 19,510.17%๐Ÿ‡บ๐Ÿ‡ธ USA
C$73.85 B 26,334.21%๐Ÿ‡บ๐Ÿ‡ธ USA
C$86.77 B 30,961.74%๐Ÿ‡บ๐Ÿ‡ธ USA
C$51.36 B 18,286.18%๐Ÿ‡บ๐Ÿ‡ธ USA
C$95.71 B 34,160.07%๐Ÿ‡บ๐Ÿ‡ธ USA
C$4.68 M-98.32%๐Ÿ‡บ๐Ÿ‡ธ USA
C$55.57 M-80.11%๐Ÿ‡บ๐Ÿ‡ธ USA